{"ATC Code":["N - Nervous system","N05 - Psycholeptics","N05A - Antipsychotics","N05AH - Diazepines, oxazepines, thiazepines and oxepines","N05AH04","N05AH04","N05AH04 - Quetiapine","QN - Nervous system","QN05 - Psycholeptics","QN05A - Antipsychotics","QN05AH - Diazepines, oxazepines, thiazepines and oxepines","QN05AH04 - Quetiapine"],"Absorption, Distribution and Excretion":"Quetiapine is rapidly and well absorbed after administration of an oral dose. Steady-state is achieved within 48 hours and peak plasma concentrations are achieved within 1.5 hours. The steady-state Cmax of quetiapine in Han Chinese patients with schizophrenia after a 300 mg oral dose of the extended released formulation was approximately 467 ng/mL and the AUC at steady-state was 5094 ng·h/mL. While the absolute bioavailability has not been fully elucidated and is reported to be low, the tablet formulation is 100% bioavailable relative to solution. Absorption of quetiapine is affected by food, with Cmax increased by 25% and AUC increased by 15%.","Adverse Effects":"As with any antipsychotic drug, quetiapine is associated with an increased risk of death in dementia-related psychosis in elderly patients. Alongside this risk, neuroleptic malignant syndrome should be a consideration due to its D2 receptor blockage. It is the least likely of atypical antipsychotics to cause extrapyramidal symptoms. There is an increased risk for suicidal thoughts and behavior associated with drug treatment in major depressive disorder patients. Somnolence, orthostatic hypotension, and dizziness are the most common side effects of quetiapine. Somnolence and dizziness are due to the nature of quetiapine’s antagonism of H1 receptors, while antagonism causes hypotension for alpha-1 receptors. Stroke, myocarditis, and coronary heart disease have also correlated with the use of this drug.","Aliases":["quetiapina","Norsic","quetiapinum","2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol","Quetiapine extended release","NSC-758918","2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol","Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-","CHEBI:8707","Dtxcid903546","Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-","Seroquel XL","2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol","2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-ylpiperazin-1-yl)ethoxy)ethanol","Tenprolide xl","Biquelle xl","Brancico xl","Mintreleq xl","Seotiapim xl","Atrolak xl","Ebesque xl","Psyquet xl","Sondate xl","Zaluron xl","2-(2-(4-benzo(b)(1,4)benzothiazepin-6-ylpiperazin-1-yl)ethoxy)ethanol","2-(2-(4-benzo(b)(1,5)benzothiazepin-6-ylpiperazin-1-yl)ethoxy)ethanol","2-[2-(4-benzo[b][1,5]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol","2-(2-(4-(2-thia-9-azatricyclo(9.4.0.0^(3,8))pentadeca-1(11),3(8),4,6,9,12,14-heptaen-10-yl)piperazin-1-yl)ethoxy)ethan-1-ol","2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol","N05AH04","2-(2-(4-(2-thia-9-azatricyclo(9.4.0.03,8)pentadeca-1(15),3,5,7,9,11,13-heptaen-10-yl)piperazin-1-yl)ethoxy)ethan-1-ol","Seroquel","Mfcd00866699","Quetiapine-d4Hemifumarate","CHEMBL716","Ketipinor","s5741","FK949E","Ncgc00095911-03","Co-Quetiapine","Smr000550491","Cas-111974-69-7","Sr-01000759335","HSDB 7557","2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethan-1-ol","2-{2-[4-(Dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl]ethoxy}ethan-1-ol","Dibenzo[b,f][1,4]thiazepine, ethanol deriv.; 2-[2-[4-(Dibenzo[b,f][1,4]thiazepin-11-yl)-1-piperazinyl]ethoxy]ethanol; Ketipinor; Quetiapine; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-","GTPL50","Schembl7932","Mls001165710","Mls001195658","Bidd:gt0279","Spectrum1505187","orb1310882","Schembl29360153","Urkomymaxpyinw-uhfffaoysa-","GLXC-03199","HMS2093K06","HMS2231O11","HMS3372B05","HMS3744E21","HMS3886C22","HMS5085K21","Pharmakon1600-01505187","MSK10227","Tox21_111537","Bdbm50095890","EBC-26881","HY-14544R","NSC758918","NSC801189","STL373578","11-[4-[2-(2-Hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo[b,f][1,4]thiazepine","2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol","Akos003588973","Tox21_111537_1","CCG-213347","CS-1171","DB01224","FQ32483","NSC 758918","NSC-801189","Mrf-0000010","Ncgc00095911-01","Ncgc00095911-04","Ncgc00095911-06","AC-37642","AS-35258","HY-14544","Sbi-0206776.p001","NS00010395","C07397","D08456","En300-708802","Ab00640033-09","Ab00640033-10","Ab00640033_11","Ab00640033_12","L001200","Sr-01000759335-5","Sr-01000759335-7","Brd-k68867920-001-05-2","Brd-k68867920-001-11-0","Brd-k68867920-051-11-5","2-(2-(4-dibenzo[b,f]-[1,4]thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol","2-(2-(4-dibenzo[b,f][1,4] thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol","(E)-2-(2-(4-(Dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethanol","2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol","InChI=1/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2"],"Biological Half-Life":"The average terminal half-life of quetiapine is about 6-7 hours.","Boiling Point":"556.5±60.0","CAS":"111974-69-7","Chemical Classes":"Thiazepines","ChemicalClasses":["1-benzylpiperazine"],"Chirality":"achiral","Color/Form":"Solid","DBI-IGS":["Quetiapine"],"DTXSID":"9023546","Dosing Info":[{"Method":"Oral","Tiers":{"Common":{"Entries":0,"Lower":25,"Percentage":0,"Unit":"mg","Upper":25},"Extreme":{"Entries":5,"Lower":115,"Percentage":10.4,"Unit":"mg","Upper":115},"Heavy":{"Entries":1,"Lower":50,"Percentage":2.1,"Unit":"mg","Upper":115},"Light":{"Entries":33,"Lower":25,"Percentage":68.8,"Unit":"mg","Upper":25},"Strong":{"Entries":9,"Lower":25,"Percentage":18.8,"Unit":"mg","Upper":50}}}],"Drug Classes":["Breast Feeding","Lactation","Milk, Human","Antipsychotic Agents"],"Drug Indication":"Quetiapine is used in the symptomatic treatment of schizophrenia.  In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.  Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.","Drug Warnings":"/BOXED WARNING/ WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA- RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS:  Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Quetiapine is not approved for the treatment of patients with dementia-related psychosis.    Suicidal Thoughts and Behaviors:  Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.  Quetiapine is not approved for use in pediatric patients under ten years of age.","EliminationHalfLife":"7 hours (parent compound); 9 – 12 hours (active metabolite, norquetiapine)Truven Health Analytics, Inc. DrugPoint System (Internet) [cited 2013 Sep 18]. Greenwood Village, CO: Thomsen Healthcare; 2013.","Erowid Experience Reports":[{"Author":"Narr","Id":72032,"Title":"No Go"},{"Author":"Plutonium Boss","Id":52490,"Title":"The Dysphoria Drug"},{"Author":"ChiaPetOG","Id":90335,"Title":"Less Anxious and More Relaxed"},{"Author":"Anonymous","Id":56988,"Title":"Mild Hallucinations and Disorientation"},{"Author":"MDW","Id":82192,"Title":"So Far So Good"},{"Author":"Guani","Id":27668,"Title":"How I Got My Life Back"},{"Author":"Xdefeatsy","Id":60641,"Title":"Suicide Prevention"},{"Author":"Stretch","Id":20582,"Title":"Sleepy Nights and Mornings"},{"Author":"Gengis Kaine","Id":16165,"Title":"Effect of 'Atypical' Psychotropic with Meth"},{"Author":"Mike","Id":68622,"Title":"Appreciating the Benefits"},{"Author":"Lotus Blossom","Id":76988,"Title":"Recreation?"},{"Author":"Durandal","Id":78705,"Title":"Treats Withdrawal"},{"Author":"selected","Id":79592,"Title":"I Would Never Take It Again"},{"Author":"WatersMoon110","Id":79596,"Title":"Cool Visuals"},{"Author":"EvanesEmperor","Id":79918,"Title":"Peeking Into the Abyss of a Cure"},{"Author":"SaySho","Id":81399,"Title":"Beware of Seroquel with Weed"},{"Author":"Bow","Id":65010,"Title":"D.O.C. of Institutions"},{"Author":"syrossoul","Id":81598,"Title":"I Was Short of Breath"},{"Author":"Danyv","Id":76767,"Title":"For Opiate Wthdrawals"},{"Author":"far2farside8","Id":74305,"Title":"Poor Luck with Newer Atypical Antipsychotic"},{"Author":"far2farside8","Id":74291,"Title":"Worked for a While"},{"Author":"Dmanic","Id":68725,"Title":"Nightly Vivid Dreams"},{"Author":"Herr Mannelig","Id":69010,"Title":"Its Great if Used Responsibly"},{"Author":"bugman","Id":66285,"Title":"Zombie Life Saver"},{"Author":"Gigaza","Id":69636,"Title":"Works Well as a Sleep-Aid"},{"Author":"Max_AvA","Id":71071,"Title":"To Solve a Bad Trip"}],"Esters":[],"European Community (EC) Number":"601-143-7","FDA Pharmacological Classification":[{"Name":"FDA UNII","ReferenceNumber":27,"Value":{"StringWithMarkup":[{"String":"BGL0JSY5SI"}]}},{"Name":"Active Moiety","ReferenceNumber":27,"Value":{"StringWithMarkup":[{"String":"QUETIAPINE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":27,"Value":{"StringWithMarkup":[{"String":"Established Pharmacologic Class [EPC] - Atypical Antipsychotic"}]}},{"Name":"FDA Pharmacology Summary","ReferenceNumber":27,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-5002","Length":10,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Quetiapine"}],"String":"Quetiapine is an Atypical Antipsychotic."}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":59,"Value":{"StringWithMarkup":[{"String":"QUETIAPINE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":59,"Value":{"StringWithMarkup":[{"String":"Atypical Antipsychotic [EPC]"}]}}],"Flash Point":"9.7 °C (49.5 °F) - closed cup","Formating":[],"HMDB ID":"HMDB0005021","Health Effects":"Tachycardia, development of tardive dyskinesia, an incurable neurological disorder, and a neuroleptic malignant syndrome may result from use or overdose of Quetiapine (L1125).","HeavyAtomCount":27,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antipsychotic Agents","IUPACName":"2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol","InChI":"InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2","InChIKey":"URKOMYMAXPYINW-UHFFFAOYSA-N","Interactions":"Coadministration of quetiapine (250 mg) and phenytoin (100 mg) increased the mean oral clearance of quetiapine by 5-fold. Increased doses of quetiapine may be required to maintain control of symptoms of schizophrenia in patients receiving quetiapine and phenytoin, or other hepatic enzyme inducers (e.g., carbamazepine, barbiturates, rifampin, glucocorticoids). Caution should be taken if phenytoin is withdrawn and replaced with a non-inducer (e.g., valproate)","KEGG Entries":[{"Id":"D00458","Interactions":[{"Action":"inhibition","Target":"CYP3A4"},{"Action":"induction","Target":"CYP3A4"}],"Synonyms":["Quetiapine fumarate","Seroquel"]},{"Id":"D08456","Interactions":[{"Action":"induction","Target":"CYP3A4"},{"Action":"inhibition","Target":"CYP3A4"}],"Synonyms":["Quetiapine","Norsic"]},{"Id":"D08456","Interactions":[{"Action":"induction","Target":"CYP3A4"},{"Action":"inhibition","Target":"CYP3A4"}],"Synonyms":["Quetiapine","Norsic"]}],"MeSH Headers":[{"Id":"M0189762","Link":"https://id.nlm.nih.gov/mesh/M0189762.html","Name":"Quetiapine","Ref":90},{"Id":"DescTree","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":"MeSH Tree","Ref":91},{"Id":"M0001384","Link":"https://id.nlm.nih.gov/mesh/M0001384.html","Name":"Antidepressive Agents","Ref":117},{"Id":"M0021770","Link":"https://id.nlm.nih.gov/mesh/M0021770.html","Name":"Antipsychotic Agents","Ref":118}],"MeSH Pharmacological Classification":[{"Id":"M0001384","Link":"https://id.nlm.nih.gov/mesh/M0001384.html","Name":"Antidepressive Agent","Ref":117},{"Id":"M0021770","Link":"https://id.nlm.nih.gov/mesh/M0021770.html","Name":"Antipsychotic Agent","Ref":118}],"Mechanism of Action":"Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine's actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 receptors, respectively.","Melting Point":"174-176","Metabolism/Metabolites":"The metabolism of quetiapine occurs mainly in the liver. Sulfoxidation and oxidation are the main metabolic pathways of this drug. According to in vitro studies, cytochrome P450 3A4 metabolizes quetiapine to an inactive sulfoxide metabolite and also participates in the metabolism of its active metabolite, N-desalkyl quetiapine. CYP2D6 also regulates the metabolism of quetiapine. In one study, three metabolites of N-desalkylquetiapine were identified. Two of the metabolites were identified as N-desalkylquetiapine sulfoxide and 7-hydroxy-N-desalkylquetiapine. CYP2D6 has been found to be responsible for metabolism of quetiapine to 7-hydroxy-N-desalkylquetiapine, a pharmacologically active metabolite. Individual differences in CYP2D6 metabolism may be present, which may affect the concentrations of the active metabolite.","MolecularFormula":"C\u003csub\u003e21\u003c/sub\u003eH\u003csub\u003e25\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003eS","MolecularWeight":"383.5 g/mol","Pharmacodynamics":"Quetiapine improves the positive and negative symptoms of schizophrenia and major depression by acting on various neurotransmitter receptors, such as the serotonin and dopamine receptors. In bipolar disorder, it improves both depressive and manic symptoms.  **A note on suicidality in young patients and administration in the elderly**  Quetiapine can cause suicidal thinking or behavior in children and adolescents and should not be given to children under 10 years of age. It is important to monitor for suicidality if this drug is given to younger patients. In addition, this drug is not indicated for the treatment of psychosis related to dementia due to an increased death rate in elderly patients taking this drug.","Physical Description":"Solid","PubChemId":5002,"Record Description":["LiverTox|CNS|Antipsychotic|Atypical"],"Records":{"UNII":{"Impurities":[]}},"RefChem":"6192","RefCount":4,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Quetiapine","Name":"Quetiapine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q408535","Name":"Quetiapine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/DB01224","Name":"Quetiapine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5002","Name":"Quetiapine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=111974-69-7","Name":"Quetiapine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005021","Name":"Quetiapine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07397","Name":"Quetiapine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/BGL0JSY5SI","Name":"Quetiapine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID9023546","Name":"Quetiapine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 5002, quetiapine. Accessed May 17, 2026. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/5002\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/5002\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Quetiapine. UNII: BGL0JSY5SI. Global Substance Registration System. Accessed May 17, 2026. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/BGL0JSY5SI\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/BGL0JSY5SI\u003c/a\u003e","Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. June 21, 2022. Accessed May 17, 2026. \u003ca href=https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017\u003ehttps://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017\u003c/a\u003e"],"SMILES":"C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42","SaltData":[],"Salts":[],"Scheduling":[{"gov":"Australia","ref":["3"],"schedule":"S4 substance"},{"gov":"Brazil","ref":[],"schedule":"C1 substance"},{"gov":"Canada","ref":[],"schedule":"prescription only substance"},{"gov":"New Zealand","ref":[],"schedule":"Prescription only substance"},{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"}],"Solubility":"49.4 [ug/mL] (The mean of the results at pH 7.4)","Stability/Shelf Life":"Stable under recommended storage conditions.","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 165.261 87.605\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h166v88H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m78.951 60.371-13.198-7.62M65.753 52.751l-10.05 5.807M52.549 64.23l-.004 11.398M52.545 75.628l13.198 7.62M65.743 83.248l10.05-5.807M78.951 60.371l-.003 11.399M82.1 77.44l10.045 5.8M92.145 83.24l13.198-7.62M105.343 75.62l9.914 5.724M121.819 81.347l9.92-5.727M131.739 75.62l13.199 7.62M144.938 83.24l9.917-5.726M49.397 58.559 39.352 52.76\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m39.352 52.76.871-11.35M37.01 51.408l.782-10.184\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m40.223 41.41-.436 5.675M37.792 41.224l-.391 5.092\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m37.556 34.786-8.159-7.654\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m29.397 27.132 5.569-14.144M27.642 24.935l4.54-11.532\"/\u003e\u003c/g\u003e\u003cpath d=\"M34.966 12.988 25.489 1.052\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M25.489 1.052 10.434 3.361M24.459 3.677 12.19 5.558\"/\u003e\u003c/g\u003e\u003cpath d=\"M10.434 3.361 4.865 17.505\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m4.865 17.505 9.477 11.936M7.649 17.09l7.723 9.726\"/\u003e\u003c/g\u003e\u003cpath d=\"m29.397 27.132-15.055 2.309M14.342 29.441l-5.603 9.668M8.111 46.206l4.132 10.587\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M12.243 56.793 1.055 67.143M12.86 59.544l-9.117 8.434\"/\u003e\u003c/g\u003e\u003cpath d=\"M1.055 67.143 4.4 81.971\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m4.4 81.971 14.526 4.58M6.47 80.067 18.309 83.8\"/\u003e\u003c/g\u003e\u003cpath d=\"m18.926 86.551 11.188-10.35\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m30.114 76.201-3.345-14.829M27.426 75.366l-2.728-12.09\"/\u003e\u003c/g\u003e\u003cpath d=\"m12.243 56.793 14.526 4.579M39.352 52.76l-12.583 8.612\" class=\"bond\"/\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M54.491 62.829h-.721l-2.619-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566V57.93h.715l2.607 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482V57.93h.578zM80.887 78.069h-.72l-2.619-4.066h-.03l.03.596q.023.357.023.732v2.738h-.565V73.17h.714l2.608 4.054h.029l-.017-.327-.024-.477q-.006-.262-.006-.482V73.17h.577z\" class=\"atom\"/\u003e\u003cpath stroke=\"none\" d=\"M120.8 83.237q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.863 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M160.395 75.617q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.863 0q0 .922.386 1.458.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.208-.524-.834 0-1.227.524-.392.524-.392 1.453M164.701 78.069h-.619v-2.286h-2.512v2.286h-.613V73.17h.613v2.072h2.512V73.17h.619z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M42.459 40.014h-.72l-2.62-4.066h-.03l.03.595q.024.358.024.733v2.738h-.565v-4.899h.714l2.607 4.054h.03l-.018-.328-.024-.476q-.005-.262-.005-.482v-2.768h.577z\" class=\"atom\"/\u003e\u003cpath fill=\"#c6c62c\" stroke=\"none\" d=\"M8.253 43.749q0 .648-.476 1.018-.471.363-1.268.363-.417 0-.768-.066-.346-.059-.578-.172v-.59q.244.113.607.203.369.089.762.089.548 0 .828-.214.28-.215.28-.578 0-.238-.108-.399-.101-.166-.351-.309t-.696-.298q-.625-.226-.947-.554-.315-.333-.315-.899 0-.392.196-.666.203-.28.554-.429.357-.155.815-.155.405 0 .739.078.339.071.613.196l-.197.53q-.25-.113-.547-.185-.298-.077-.626-.077-.458 0-.69.197-.232.196-.232.517 0 .245.101.411.107.167.339.298.232.125.631.28.429.154.727.339.297.179.452.435.155.25.155.637\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m55.703 58.558 5.025-2.904M52.549 64.23l-.002 5.699M75.793 77.441l-5.025 2.904M78.948 71.77l.002-5.7M82.1 77.44l5.023 2.9\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m115.257 81.344-4.957-2.862M121.819 81.347l4.96-2.864M154.855 77.514l-4.958 2.863\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m49.397 58.559-5.023-2.9M37.556 34.786l-4.079-3.827\" class=\"hi\"/\u003e\u003cpath stroke=\"#c6c62c\" d=\"m8.739 39.109 2.802-4.834M8.111 46.206l2.066 5.293\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Therapeutic Uses":"Antipsychotic Agents","Title":"Quetiapine","Treatment":"There is no specific antidote. Treat quinidine-like cardiotoxic effects with bicarbonate. Maintain an open airway and assist ventilation if necessary. Administer supplemental oxygen. (L304)","UNII":"BGL0JSY5SI","Wikidata":"Q408535","Wikipedia":"Quetiapine","XLogP":2.1}